Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications
L Dayon, O Cominetti, M Affolter - Expert review of proteomics, 2022 - Taylor & Francis
Introduction Biological fluids are routine samples for diagnostic testing and monitoring.
Blood samples are typically measured because of their moderate invasive collection and …
Blood samples are typically measured because of their moderate invasive collection and …
Myelin in Alzheimer's disease: culprit or bystander?
M Maitre, H Jeltsch-David, NG Okechukwu… - Acta Neuropathologica …, 2023 - Springer
Alzheimer's disease (AD) is a neurodegenerative disorder with neuronal and synaptic
losses due to the accumulation of toxic amyloid β (Αβ) peptide oligomers, plaques, and …
losses due to the accumulation of toxic amyloid β (Αβ) peptide oligomers, plaques, and …
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease
Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …
Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level
The biological processes that are disrupted in the Alzheimer's disease (AD) brain remain
incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain …
incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain …
Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and …
Our understanding of Alzheimer's disease (AD) pathophysiology remains incomplete. Here
we used quantitative mass spectrometry and coexpression network analysis to conduct the …
we used quantitative mass spectrometry and coexpression network analysis to conduct the …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature aging, 2024 - nature.com
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Human CNS barrier-forming organoids with cerebrospinal fluid production
L Pellegrini, C Bonfio, J Chadwick, F Begum, M Skehel… - Science, 2020 - science.org
INTRODUCTION The choroid plexus is a secretory epithelial tissue of the central nervous
system (CNS) responsible for cerebrospinal fluid (CSF) production and functions as a barrier …
system (CNS) responsible for cerebrospinal fluid (CSF) production and functions as a barrier …
[HTML][HTML] Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression
Alzheimer's disease (AD) displays a long asymptomatic stage before dementia. We
characterize AD stage-associated molecular networks by profiling 14,513 proteins and …
characterize AD stage-associated molecular networks by profiling 14,513 proteins and …
Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer's
disease and its diverse pathological processes are urgently needed. Here, we undertook an …
disease and its diverse pathological processes are urgently needed. Here, we undertook an …
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …